Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 5:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Kenalog Injectable Product Clear all
Terminated Phase 4 Interventional Results available

Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata

NCT05278858
View directory record Official record
Conditions
Alopecia Areata
Interventions
MedJet Device with intralesional triamcinolone
Combination Product
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
6 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 21, 2026, 5:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Single-Center Investigator-Initiated Evaluator-Bilateral-Comparison Pilot Study of Injectable Calcium Hydroxylapatite With and Without Triamcinolone Acetate for the Treatment of Volume Loss to Dorsum Areas of the Hands

NCT02454088
View directory record Official record
Conditions
Volume Loss to Dorsum of Hands
Interventions
Calcium Hydroxylapatite and Triamcinolone acetate, Calcium Hydroxylapatite and Placebo
Other · Device
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 21, 2026, 5:57 AM EDT
Terminated Phase 1 Interventional

ZILRETTA™ for Treatment of Idiopathic Adhesive Capsulitis

NCT04831255
View directory record Official record
Conditions
Adhesive Capsulitis, Frozen Shoulder, Adhesive Capsulitis of Shoulder
Interventions
triamcinolone acetonide extended-release injectable suspension
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 21, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis

NCT03097315
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
4 mg CLS-TA Suprachoriodal Injection
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 21, 2026, 5:57 AM EDT
Recruiting Phase 4 Interventional

Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes

NCT06478186
View directory record Official record
Conditions
Osteoarthritis, Knee, Diabetes Mellitus, Type 2
Interventions
triamcinolone acetonide extended-release injectable suspension; TCA-ER, Triamcinolone Acetonide- Immediate Release;TCA-IR
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 21, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02303184
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
4 mg CLS-TA, Sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Beverly Hills, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Sep 21, 2026, 5:57 AM EDT
Terminated Not applicable Interventional Results available

Intraarticular Corticosteroid Therapy in Perthes Disease.

NCT01026909
View directory record Official record
Conditions
Legg-Calve Perthes Disease
Interventions
Aristospan 20mg
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
4 Years to 13 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 21, 2026, 5:57 AM EDT
Terminated Phase 4 Interventional Results available

Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement

NCT02920177
View directory record Official record
Conditions
Femoroacetabular Impingement
Interventions
platelet-rich plasma injection, Kenalog 10 MG/ML Injectable Suspension
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 21, 2026, 5:57 AM EDT
Completed Not applicable Interventional Results available

Steroid Injection vs. BioDRestore for Patients With Knee OA

NCT02767492
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
BioD Restore, Kenalog
Device · Drug
Lead sponsor
The Hawkins Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 21, 2026, 5:57 AM EDT
Completed Phase 4 Interventional Results available

Effect of Steroid Injections in a Knee With Osteoarthritis

NCT01230424
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee
Interventions
Triamcinolone Acetonide, 0.9% Sodium Chloride Injection as Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
45 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 21, 2026, 5:57 AM EDT
Withdrawn Phase 1 Interventional

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

NCT04655391
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia
Interventions
Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate, Gilteritinib Fumarate, Glasdegib Maleate, Ivosidenib, Venetoclax
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 21, 2026, 5:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Kybella With Triamcinolone

NCT03361176
View directory record Official record
Conditions
Adiposity
Interventions
Injectable sodium deoxycholate, Injectable sodium deoxycholate with Triamcinolone acetate
Drug · Combination Product
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
San Diego, California • Hunt Valley, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 21, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

NCT02255032
View directory record Official record
Conditions
Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Anterior, Panuveitis, Uveitis, Intermediate
Interventions
4 mg CLS-TA, 0.8 mg CLS-TA
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Sep 21, 2026, 5:57 AM EDT
Completed Not applicable Interventional

Randomized Controlled Trial of Endoscopic Dilation: Triamcinolone Injection

NCT01873573
View directory record Official record
Conditions
Dysphagia
Interventions
Dilation, Triamcinolone Injection, Esophagogastroduodenoscopy (EGD)
Procedure · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Sep 21, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional Results available

Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury

NCT04331002
View directory record Official record
Conditions
Tibial Meniscus Injuries, Tibial Meniscus Tears, Tibial Meniscus, Torn, Anterior Cruciate Ligament Tear
Interventions
Zilretta, Placebo
Drug · Other
Lead sponsor
Austin V Stone
Other
Eligibility
18 Years to 40 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 21, 2026, 5:57 AM EDT
Completed Phase 4 Interventional

Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance

NCT05058209
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Triamcinolone acetonide extended-release injectable suspension, Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension
Drug
Lead sponsor
ROC Foundation
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced Sep 21, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Study of FX006 in Patients With Osteoarthritis of the Knee

NCT01487161
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
FX006, TCA IR
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Tucson, Arizona • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 21, 2026, 5:57 AM EDT
Withdrawn Phase 4 Interventional

Suprascapular Nerve Block for Treatment of Shoulder Pain in Individuals With Spinal Cord Injuries

NCT05364099
View directory record Official record
Conditions
Chronic Shoulder Pain
Interventions
Lidocaine 1% Injectable Solution, Triamcinolone Injection, Suprascapular Nerve Block
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 21, 2026, 5:57 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip

NCT06977568
View directory record Official record
Conditions
Osteoarthritis of Hip
Interventions
Zilretta, Triamcinolone Acetonide
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
50 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 21, 2026, 5:57 AM EDT
Completed Phase 1 Interventional

Effect of Zilretta Injection

NCT04261049
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Triamcinolone Acetonide Extended-Release Injectable Suspension
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Sep 21, 2026, 5:57 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Intra-articular Bilateral Knee Injections of Zilretta on Performance Measures in Adults With Knee OA

NCT03895840
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Zilretta
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
30 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Sep 21, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

NCT01356602
View directory record Official record
Conditions
Acute Gouty Arthritis
Interventions
Canakinumab pre-filled syringe, Canakinumab lyophilized powder, Triamcinolone Acetonide, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
69
States / cities
Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Sep 21, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Early Treatment for Acute ACL Tear

NCT01692756
View directory record Official record
Conditions
Anterior Cruciate Ligament (ACL) Tears
Interventions
Kenalog or placebo, Kenalog then Placebo, Kenalog, Placebo
Drug
Lead sponsor
Cale Jacobs
Other
Eligibility
14 Years to 33 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 21, 2026, 5:57 AM EDT
Recruiting Phase 2 Interventional

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

NCT06315309
View directory record Official record
Conditions
GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions
ATG Combined with Tacrolimus and Mini Methotrexate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 21, 2026, 5:57 AM EDT